Evidence map›Paper›PMID 30894647›Full record

ArticleScientific reports2019

Development of a

Roger Yazbeck, Simone Jaenisch, Michelle Squire, Catherine A Abbott, Emma Parkinson-Lawrence, Douglas A Brooks, Ross N Butler

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Roger YazbeckCollege of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia. roger.yazbek@flinders.edu.au.
Simone JaenischCollege of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Michelle SquireCollege of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Catherine A AbbottFlinders Centre for Innovation in Cancer, Flinders University, Adelaide, South Australia, Australia.ORCID 0000-0001-8215-4406
Emma Parkinson-LawrenceSchool of Pharmacy and Medical Science, University of South Australia Cancer Research Institute, Adelaide, South Australia, Australia.
Douglas A BrooksSchool of Pharmacy and Medical Science, University of South Australia Cancer Research Institute, Adelaide, South Australia, Australia.
Ross N ButlerCollege of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Flinders University · AUUniversity of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dipeptidyl peptidase-4 inhibitors (DPP4i) are a class of orally available, small molecule inhibitors for the management of Type-II diabetes. A rapid, real-time, functional breath test for DPP4 enzyme activity could help to define DPP4i efficacy in patients that are refractory to treatment. We aimed to develop a selective, non-invasive, stable-isotope

Indexed as

Breath TestsCaco-2 CellsCarbon IsotopesDiabetes Mellitus, Type 2Dipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsHeLa CellsHumansSitagliptin PhosphateCarbon IsotopesDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDPP4 protein, humanSitagliptin Phosphate

Identifiers

PMID30894647
PMCPMC6427020
OpenAlexW2925003254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.